# A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis

> **NCT00502294** · PHASE3 · WITHDRAWN · sponsor: **Facet Biotech** · enrollment: 150 (estimated)

## Conditions studied

- Intravenous Steroid-Refractory Ulcerative Colitis

## Interventions

- **DRUG:** Visilizumab (HuM291; Nuvion®)

## Key facts

- **NCT ID:** NCT00502294
- **Lead sponsor:** Facet Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2009-06-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00502294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00502294, "A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00502294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*